Research into hypertension has tended to concentrate on the vascular system that contains the blood within it, or on the molecules transported by the blood, rather than the properties of the blood itself. Blood is a living fluid whose properties can vary dramatically in health and disease. The properties of a fluid (in this case, blood) tend to be reflected by its physical characteristics, such as viscosity and 'density', which influence flow (in the case of blood, haemorheology). Indeed changes in haemorheological properties may be important in the pathogenesis of hypertension, have prognostic value in predicting hypertensive complications and may be altered by treatment. 1 The fundamental determinants of arterial blood pressure are cardiac output and total peripheral resistance. The latter is determined not only by the diameter of the arterioles but also the physical characteristics of blood flowing through them. In particular, blood viscosity is important, but is itself determined by the haematocrit, the plasma viscosity (the principal contributor to which is fibrinogen) and the physical properties of the red blood cells themselves. However, as blood contains cells and macromolecules, it behaves in a non-Newtonian manner, with its viscosity changing at different shear rates. At the high shear rates, found in the microvessels that are the major sites of vascular resistance, it is the red cell deformabilty which is the major contributor to whole blood viscosity. 2 Red cell deformability is not a parameter which is easily measured at the level of the individual cell, but may be estimated from the relative blood viscosity, that is, the ratio of whole blood viscosity at high shear rates to plasma viscosity. 3 A number of studies have found increases in whole blood viscosity in hypertensives compared to controls, with strong correlations with blood pressure. 2, [4] [5] [6] The relationship between blood viscosity and blood pressure holds true even in those with borderline hypertension, 3 suggesting that the elevation in blood viscosity is not simply a consequence of long term hypertension. A raised haematocrit in hypertensives has not been shown in all studies, Correspondence: Dr GYH Lip Received and accepted 10 February 2000 despite the presence of other abnormal rheological indices, suggesting that the haemorheological abnormalities in hypertension are unlikely just to be due to haemoconcentration, perhaps from diuretic usage. 4, 7 It is of interest that patients with polycythaemia often have hypertension 8 and that the use of erythropoietin to treat anaemia in chronic renal disease results in a rise in blood pressure. 9 Another haemorheological index, plasma viscosity, is also modestly elevated in hypertensives, 4, 10 and this may be relevant to the prothrombotic state in hypertension, 1 since some plasma proteins which are clotting factors are major contributors to plasma viscosity. In particular, plasma fibrinogen is a major component of plasma viscosity and an acute phase protein, as well as a key component of the coagulation system. There are correlations between fibrinogen and blood pressure in both case control and population studies, and the degree of elevation is greater than would be expected from haemoconcentration alone. 5, 6 Why are these haemorheological changes in hypertension of importance? Firstly, these changes may be involved in the pathogenesis of hypertension. Although many of the changes in haemorheology may be secondary to vasoconstriction resulting from derangement of the sympathetic nervous system or the renin angiotensin system, it is possible that a primary increase in blood viscosity could lead to hypertension by increasing peripheral vascular resistance. The increased incidence of hypertension in patients with polycythaemia and the rise in blood pressure in those treated with erythropoietin provide a model for this. Sadly this area of research is consistently plagued with 'chicken and egg' arguments. It is of note that abnormalities of erythrocyte deformability, although not of whole blood viscosity or fibrinogen, may be found in adolescent hypertensives. 11 Perhaps the most important reason that haemorheological changes in hypertension deserve further study is their prognostic significance. It is a paradox that in hypertension the vessel walls are exposed to increased pressures, but the majority of complications of hypertension (that is, heart attacks and strokes) are thrombotic rather than haemorrhagic in nature. Any changes in blood characteristics that lead to a prothrombotic or hypercoagulable state would be expected to increase the chance of developing these complications. 1 However, there are limited data on the prognostic value of haemorheological factors in hypertensive populations. Nevertheless, the issue has been addressed in several large epidemiological studies. For example, the Edinburgh Artery Study found that plasma viscosity levels were significantly higher in those who suffered a cardiovascular event.
12 Similar findings were reported in the larger Caerphilly and Speedwell study 13 and the recent MONICAAugsberg cohort study.
14 A Norwegian survey of 488 middle-aged employed men found that a two standard deviation increase in haematocrit was associated with a 2.9-fold increased risk of coronary heart disease mortality at 10 years, even after correction for smoking, cholesterol and systolic blood pressure. 15 An increased risk for major ischaemic heart disease events has also been reported in the British Regional Heart Study 16 as well as the Framingham study. 17 A number of studies have also demonstrated a clear relationship between increased plasma fibrinogen levels and risk of cardiovascular disease. 18, 19 In the Leigh general practice study, hypertensive subjects with plasma fibrinogen levels Ͼ3.5 g/l had a 12-fold higher cardiovascular risk than those with plasma fibrinogen levels Ͻ2.9 g/l. 20 Perhaps because it is more difficult to measure, whole blood viscosity has not been examined in the large epidemiological studies but this index has been related to other markers of cardiovascular risk. For example, Devereux et al 21 found that whole blood viscosity was closely correlated with left ventricular mass, a powerful marker for increased risk in hypertension. Similarly Lee et al 22 found an increased rate of progression of carotid atherosclerosis in patients with higher whole blood viscosity.
Thus the role of haemorheological parameters in the pathogenesis and prognosis of hypertension is likely to be significant, and therefore the effects of antihypertensive drugs on these parameters may be of importance. In theory an antihypertensive agent which has favourable effects on haemorheology could be expected to be better at preventing the complications of hypertension than one with unfavourable effects. 1 This might explain some of the differences in outcome in the long-term studies using different antihypertensive agents. For example, thiazides are particularly effective in older hypertensives at preventing myocardial infarction and stroke. 23 In contrast, the Multiple Risk Factor Intervention Trial reported that hypertensive patients treated with diuretics had an increased mortality if electrocardiographic changes of left ventricular hypertrophy were present. 24 Indeed, plasma fibrinogen levels are higher amongst hypertensive patients with left ventricular hypertrophy. 25 Nevertheless, the available data on the effects of drugs on haemorrheological indices in hypertensives has been largely derived from fairly small, short term studies. For example, hydrochlorothiazide increased fibrinogen and plasma viscosity and decrease red blood cell deformability after 2 weeks, whilst felodipine had no effect. 26 Another study also found that hydrochlorothiazide had unfavourable effects on erythrocyte aggregation time and diaggregation shear rate. 27 By contrast beta-blockers may have a favourable effect on fibrinogen, haematocrit and whole blood viscosity, 28 whilst the alphablocker, terazosin, can reduce whole blood viscosity and improve red cell deformability. 29 Of the calcium antagonists, amlodipine has been shown to decrease whole blood viscosity, plasma viscosity and improve erythrocyte fluidity, 28 whilst nitrendipine improves both blood viscosity and erythrocyte deformability. 30 The angiotensin-converting enzyme inhibitor, lisinopril, has beneficial effects on erythrocytes, 27 while cilazapril can actually increase whole blood viscosity at low shear rates. 31 The few studies that have taken place with angiotensin II receptor blockers have found no effect on plasma fibrinogen 32 or other haemorheological indices. 33 In this issue of the Journal of Human Hypertension, Shand et al 34 report changes in erythrocyte deformability and whole blood viscosity in hypertensive patients who treated with angiotensin II antagonists or angiotensin-converting enzyme inhibitors. The increased red cell deformability following losartan treatment was balanced by an increase in plasma viscosity. The paper by Shand et al 34 is the first report of an adverse effect on plasma viscosity in hypertension with losartan but this needs confirmation in a larger study. Furthermore, are the changes in haemorheology simply secondary to changes in blood pressure or can the study of haemorheological variables in hypertension improve our treatment and perhaps tell us something about the pathogenesis of a disease that is often unsatisfactorily labelled as 'essential' in over 90% of cases?
What all these studies cannot tell us is whether these changes are due to direct effects of the drugs on, for example, the erythrocyte membrane or the actual production of fibrinogen, or whether the haemorheological changes are simply secondary to blood pressure lowering and other haemodynamic changes. Elucidating these complex interactions is likely to prove taxing for the most dedicated researcher. Meanwhile for the patient and physician, perhaps the most important question is whether the different haemorheological changes brought about by the various classes of antihypertensive drugs translate into real differences in longterm outcome. These questions can only be addressed by carefully studying haemorheological variables in large numbers of hypertensive patients taking part in clinical trials comparing different antihypertensive agents, or combinations of drugs, in unselected patients, with long follow-up periods and hard end-points.
